trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

The high cost of monoclonal antibody production is a significant barrier to their practical use in treating microbial infections.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that the high cost of monoclonal antibody production is a significant barrier to their practical use in treating microbial infections?

Yes. The high cost and complex manufacturing requirements of monoclonal antibody production present substantial barriers to their practical and equitable application in treating microbial and infectious diseases.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently support the claim that production costs, complex manufacturing infrastructure, and economic barriers limit the widespread practical and global use of monoclonal antibodies in infectious disease treatment. No papers refute this assertion.

Evidence for · 3
Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25.
2026
Highlights that global access to monoclonal antibodies for preventing infectious diseases like HIV remains constrained by high production costs and infrastructure requirements.
Get citation
TL, T., L, K., P, P., S, M., M, M., K, A., J, N., DH, B., & R, C. (2026). Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25.. doi.org. https://doi.org/10.3389/fped.2026.1837801

See more details
More for · 2
Breaking the sound barrier: global monoclonal antibody pharmacoequity.
2026
Notes that despite the great success of monoclonal antibodies, global access is profoundly inequitable largely due to cost and financial barriers.
Get citation
HC, G., G, G., & B, K. (2026). Breaking the sound barrier: global monoclonal antibody pharmacoequity.. doi.org. https://doi.org/10.3389/fped.2026.1845146

Antibody engineering for SFTS treatment: frontier progress and translational challenges.
2026
Identifies cost control and manufacturing processes as key translational challenges in developing antibody engineering strategies for treating infectious diseases like SFTS.
Get citation
X, Y., Y, L., S, C., S, L., & H, H. (2026). Antibody engineering for SFTS treatment: frontier progress and translational challenges.. doi.org. https://doi.org/10.3389/fmicb.2026.1888718

What does the evidence say?

The retrieved papers consistently support the claim that production costs, complex manufacturing infrastructure, and economic barriers limit the widespread practical and global use of monoclonal antibodies in infectious disease treatment. No papers refute this assertion.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work